Most common pathogens are Pneumocystis jiroveci, Mycobacterium avium-intracellulare complex, Streptococcus pneumoniae, Haemophilus species. Less frequent pathogens are Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, cytomegalovirus (CMV), and Toxoplasma gondii. Chemotherapy-induced immunodeficiency may lead to severe lung infections. Pathogens commonly associated with lung infectioins are bacteria (like Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Nocardia species), viruses (eg, respiratory syncytial virus, parainfluenza virus, influenza virus A and influenza B, and cytomegalovirus), and fungi (eg, Aspergillus, Fusarium, and Mucorales species, and Pneumocystis jirovecii). Double pneumonia (bilateral pneumonia)
This is a historical term for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). However, the term was and, especially by lay people, still is used to denote pneumonia affecting both lungs. Accordingly, the term double pneumonia is more likely to be used to describe bilateral pneumonia than it is ALI or ARDS. Severe acute respiratory syndrome
Severe acute respiratory syndrome (SARS) is a highly contagious and deadly type of pneumonia which first occurred in Nov-2002 after initial outbreaks in China caused by SARS-CoV/SARS-CoV-1,which almost disappeared by the month of May-2004. The second outbreak of SARS-CoV-2 started in December 2019 from Wuhan, China and was declared pandemic by WHO on 11 March 2020. SARS is caused by the SARS coronavirus, a previously unknown pathogen. By area of lung affected
Initial descriptions of pneumonia focused on the anatomic or pathologic appearance of the lung, either by direct inspection at autopsy or by its appearance under a microscope. A lobar pneumonia is an infection that only involves a single lobe, or section, of a lung.
An increase of the QT interval of more than 60 ms was detected in 1.2% of people receiving etelcalcetide.Due to the lower iPTH levels achieved by the use of this drug, it is possible that adynamic bone disease could occur at levels "below 100 pg/mL"

Contraindications
The drug is contraindicated in people with blood serum calcium levels below the norm. Chemistry
The substance is a peptide consisting mostly of D-amino acids instead of the common L-amino acids. More specifically, it is the disulfide of N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide with L-cysteine. History
Originally, Etelcalcetide was being developed by KAI Pharmaceuticals. After positive Phase II trials, Amgen acquired KAI for $315 Million.In 2011, KAI entered into agreement with Ono Pharmaceutical for production of Etelcalcetide in Japan, the deal being worth ¥1 Billion.On 25 August 2015 Amgen Inc. announced its submission of a new drug application to the Food and Drug Administration for etelcalcetide. The European Medicines Agency approved the drug in November 2016.In February 2017, the FDA approved Parsabiv for the treatment of secondary hyperparathyroidism. Research
Phase II trials found that Etelcalcetide was able to lower PTH levels in one cohort by -49% vs a 29% increase in the placebo group. In another Phase II study "89% of patients experienced a C30% reduction in PTH and 56% achieved a PTH level of B300 pg/mL. "In 2017, two Phase III trials found that using etelcalcetide showed greater symptom reduction compared to placebo. Etelcalcetide was also able to lower PTH levels below 300pg/mL more often.Phase I Pediatric studies are planned for the US and UK for etelcalcetide.